MHRA research evaluates two different approaches to cancer therapies
The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.
Source: news-medical.net